According to filings with the U.S. Securities and Exchange Commission, Ember LifeSciences has raised $27 Million in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Amgen Ventures

About Ember LifeSciences
Ember LifeSciences initially launched as an offshoot of Ember Technologies’ Ember, the design-led temperature control brand and maker of the award-winning temperature control mug, which has surpassed half a billion dollars in total sales to date. Ember LifeSciences seeks to redefine global medicine distribution through leveraging Ember’s proprietary temperature control technology to improve the way we transport life-saving medicines and vaccines around the world.

To learn more, visit https://www.emberlifesciences.com/
Linkedin: https://www.linkedin.com/company/ember-lifesciences/

Contact:
Clay Alexander, Chief Executive Officer
https://www.linkedin.com/in/claytonalexander

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.